Six departments to rectify drug safety and crack down on fake sales and sales
ZHONGSHAN G.H.L. TRADING CO., LTD. , https://www.ghltrade.com
A few days ago, the State Food and Drug Administration, along with the Ministry of Health, the Ministry of Industry and Information Technology, the State Administration for Market Regulation, and the Chinese Medicine Administration, jointly released the "Special Work Plan for Drug Safety Remediation." This initiative aims to tackle a range of issues, including the spread of false advertisements through online platforms and other media, the illegal sale of counterfeit medicines via delivery services, and the promotion of non-pharmaceutical products such as food, disinfectants, health supplements, and cosmetics as if they were drugs.
In addition to targeting the production and distribution of fake medicines, this campaign will also focus on strengthening oversight of pharmaceutical manufacturing, sourcing, and quality control. It will raise the standards for drug and medical device approvals, enhance on-site inspections, and speed up the revision and management of regulatory standards. The plan also addresses violations in the drug supply chain, such as “unauthorized operations†and “ticket selling,†which have long been concerns in the industry.
Through these efforts, new systems for drug safety will be established. This includes improving regulations for pharmaceutical production and management, enhancing the monitoring and evaluation system for adverse drug reactions, refining the drug approval process, and building a more robust electronic regulatory framework. Over the next three years, the goal is to achieve real-time monitoring of the entire drug lifecycle—from production to distribution, transportation, storage, and final delivery to medical institutions—thereby significantly improving the overall capability and level of drug regulation.
As part of the initiative, public awareness campaigns on safe medication use will be launched, and a comprehensive drug safety responsibility system will be developed. Special inspections and supervision will also be conducted to ensure full compliance and accountability across the industry. This comprehensive approach reflects a strong commitment to protecting public health and ensuring the integrity of the pharmaceutical sector.